Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine with PRF for Trigeminal Postherpetic Neuralgia
NCT06914180Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of esketamine in Trigeminal postherpetic neuralgia (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Daily Mean Pain Score on Numeric Rating Scale at 7 days. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
Trigeminal postherpetic neuralgia
Beyond the preview
Go deeper on NCT06914180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06914180.